Skip to main content

Table 1 Clinicopathologic and molecular characteristics of MPA and LA cases

From: A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients

Variables MPA (n = 55) LA(n = 76) χ2 p
Gender    0.518 0.485
 Female 24(43.6%) 38(50.0%)   
 Male 31(56.4%) 38(50.0%)   
Age(years)    7.452 0.008**
> 65 20(36.4%) 46(60.5%)   
≤ 65 35(63.6%) 30(39.5%)   
Smoking history    0.191 0.723
 Ever 26(47.3%) 33(43.4%)   
 Never 29(52.7%) 43(56.6%)   
Tumor size(cm)    0.058 0.851
 > 3.0 17(30.9%) 25(32.9%)   
 ≤ 3.0 38(69.1%) 51(67.1%)   
Lymphovascular invasion    1.645 0.225
 Present 17(30.9%) 16(21.1%)   
 Absent 38(69.1%) 60(78.9%)   
Tumor differentiation    0.179 0.835
 Well/moderate 43(78.2%) 57(75.0%)   
 Poor 12(21.8%) 19(25.0%)   
N status    4.291 0.03*
 N0 31(56.4%) 56(73.7%)   
 N1/N2 24(43.6%) 20(26.3%)   
Pleural invasion    4.117 0.036*
 Present 15(27.3%) 10(13.2%)   
 Absent 40(72.7%) 66(86.8%)   
Stage    5.701 0.024*
 I/II 47(85.5%) 51(67.1%)   
 III/IV 8(14.5%) 25(32.9%)   
Mutation status     
EGFR mutation 42(76.4%) 42(55.3%) 6.175 0.016*
EML4-ALK fusion 3(5.5%) 1(1.3%) 1.846 0.309
ROS1 fusion 6(10.9%) 1(1.3%) 5.806 0.041*
  1. MPA micropapillary lung adenocarcinoma, LA lung adenocarcinoma without micropapillary component
  2. *p<0.05; **p<0.01 compared with LA